GLOW (BPC 157 10MG + GHK-CU 50mg + TB500 10mg)

GLOW is a compounded peptide blend designed for research and performance recovery applications. The formulation typically includes:

• BPC 157 – 10 mg
  A synthetic pentadecapeptide derived from a naturally occurring protein in human gastric juice.
• GHK-Cu – 50 mg
  A copper-binding tripeptide composed of glycine, histidine, and lysine, known for its role in skin and tissue regeneration.
• TB500 – 10 mg
  A synthetic peptide fragment of Thymosin Beta-4, responsible for promoting cell migration and tissue repair.

---

2. Benefits:

Each peptide in the GLOW formulation has distinct and complementary biological effects, particularly in the areas of recovery, regeneration, and inflammation modulation.

BPC 157:

• Promotes healing of soft tissues, including muscles, tendons, ligaments, and the gastrointestinal tract.
• Exhibits anti-inflammatory properties by modulating nitric oxide and cytokine pathways.
• Supports angiogenesis (formation of new blood vessels), which improves blood flow to damaged areas.
• May help protect the gut lining, based on animal models.

GHK-Cu:

• Enhances collagen production and wound healing in skin and connective tissue.
• Reduces oxidative stress and inflammation by modulating gene expression involved in tissue repair.
• May support hair growth and skin rejuvenation in cosmetic applications.
• Promotes blood vessel growth (angiogenesis) and helps maintain extracellular matrix integrity.

TB500:

• Encourages cell migration, crucial for rapid tissue repair.
• Reduces inflammation and oxidative stress in injured tissues.
• Accelerates recovery of muscles, tendons, and ligaments, particularly in overuse or trauma-related injuries.
• Supports neural regeneration and may aid in central nervous system recovery (preclinical data).

Note: While individual peptides have supportive preclinical and limited human research, combined use (as in GLOW) is experimental and not yet evaluated in large-scale clinical trials.

---

3. Dosage Protocol:

Disclaimer: The following protocol is based on research practices and should not be considered medical advice. Always consult with a qualified professional when considering peptide use in a research setting.

Typical Research Protocol for GLOW (Combination of BPC 157 + GHK-Cu + TB500):

• Administration Method:Subcutaneous (SC) injection, preferably near the site of injury for targeted benefit, or systemically (e.g., abdominal area) for general recovery.
• Dosage:
  • Total Volume: Typically reconstituted to deliver 2–3 mg of combined peptides per injection, adjusted based on the dilution and individual goals.
  • Example dose breakdown per injection (if equally divided per 10 mL vial):
    • BPC 157: ~0.5–1 mg
    • GHK-Cu: ~2–3 mg
    • TB500: ~0.5–1 mg
• Frequency:
  • 2–3 times per week, depending on injury severity, performance demands, or tissue healing goals.
• Cycle Duration:
  • Commonly used in 4–6 week cycles.
  • A maintenance phase may follow (e.g., once weekly injections) depending on ongoing needs or research goals.

---

Summary:

GLOW combines three well-studied peptides—BPC 157, GHK-Cu, and TB500—into a synergistic blend aimed at enhancing recovery, reducing inflammation, and supporting tissue regeneration. Each peptide offers unique biological actions that complement the others, making GLOW a popular investigational tool for those exploring advanced recovery and performance support protocols. While promising, combined use remains investigational and should be approached with appropriate oversight.